PET/CT–Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
home / between-the-lines / -f-fluciclovine-pet-ct-imaging-to-guide-postprostatectomy-salvage-radiotherapy-for-prostate-canc
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.
EP. 1: Phase 2/3 EMPIRE-1 Trial in Prostate Cancer
Brian Helfand, MD, PhD, NorthShore University;Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates
September 13th 2021Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.
EP. 2: Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial
Brian Helfand, MD, PhD, NorthShore University;Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates
September 20th 2021Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.
